The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Abstract
Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2-3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.Methods This randomised, open-label, phase 2-3 study was done at 50 clinical sites in China. Patients aged 18 years or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were eligible for inclusion. In the phase 2 part of the study, patients received intravenous sintilimab (200 mg every 3 weeks) plus intravenous IBI305 (15 mg/kg every 3 weeks). In the phase 3 part, patients were randomly assigned (2:1) to receive either sintilimab plus IBI305 (sintilimab-bevacizumab biosimilar group) or sorafenib (400 mg orally twice daily; sorafenib group), until disease progression or unacceptable toxicity. Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline α-fetoprotein, and ECOG performance status. The primary endpoint of the phase 2 part of the study was safety, assessed in all patients who received at least one dose of study drug. The co-primary endpoints of the phase 3 part of the study were overall survival and independent radiological review committee (IRRC)-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT03794440. The study is closed to new participants and follow-up is ongoing for long-term outcomes.Findings Between Feb 11, 2019 and Jan 15, 2020, we enrolled 595 patients: 24 were enrolled directly into the phase 2 safety run-in and 571 were randomly assigned to sintilimab-bevacizumab biosimilar (n=380) or sorafenib (n=191). In the phase 2 part of the trial, 24 patients received at least one dose of the study drug, with an objective response rate of 25·0% (95% CI 9·8-46·7). Based on the preliminary safety and activity data of the phase 2 part, in which grade 3 or worse treatment-related adverse events occurred in seven (29%) of 24 patients, the randomised phase 3 part was started. At data cutoff (Aug 15, 2020), the median follow-up was 10·0 months (IQR 8·5-11·7) in the sintilimab-bevacizumab biosimilar group and 10·0 months (8·4-11·7) in the sorafenib group. Patients in the sintilimab-bevacizumab biosimilar group had a significantly longer IRRC-assessed median progression-free survival (4·6 months [95% CI 4·1-5·7]) than did patients in the sorafenib group (2·8 months [2·7-3·2]; stratified hazard ratio [HR] 0·56, 95% CI 0·46-0·70; p<0·0001). In the first interim analysis of overall survival, sintilimab-bevacizumab biosimilar showed a significantly longer overall survival than did sorafenib (median not reached [95% CI not reached-not reached] vs 10·4 months [8·5-not reached]; HR 0·57, 95% CI 0·43-0·75; p<0·0001). The most common grade 3-4 treatment-emergent adverse events were hypertension (55 [14%] of 380 patients in the sintilimab-bevacizumab biosimilar group vs 11 [6%] of 185 patients in the sorafenib group) and palmar-plantar erythrodysaesthesia syndrome (none vs 22 [12%]). 123 (32%) patients in the sintilimab-bevacizumab biosimilar group and 36 (19%) patients in the sorafenib group had serious adverse events. Treatment-related adverse events that led to death occurred in six (2%) patients in the sintilimab-bevacizumab biosimilar group (one patient with abnormal liver function, one patient with both hepatic failure and gastrointestinal haemorrhage, one patient with interstitial lung disease, one patient with both hepatic faliure and hyperkalemia, one patient with upper gastrointestinal haemorrhage, and one patient with intestinal volvulus) and two (1%) patients in the sorafenib group (one patient with gastrointestinal haemorrhage and one patient with death of unknown cause).Interpretation Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients.Funding Innovent Biologics.Translation For the Chinese translation of the abstract see Supplementary Materials section.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305 (bevacizumab biosimilar), camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers [22, 114–120].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [119]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Cited by
Sorted by citations
Items 201–300 of 1,000
Mauro, E., & Forner, A. (2022) · Liver International · doi:10.1111/liv.15180 · Cited by 24
Wang, Z., Xu, B., Wang, L.-N., Zhu, X., Huang, C., Shen, Y., Li, H., Li, M., Zhou, J., Fan, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111863 · Cited by 25
Self-citationWang, B., Hao, X., Yan, J., Li, X., Zhao, M., & Han, T. (2024) · PubMed Central · doi:10.2478/jtim-2024-0003 · Cited by 26
Tang, H., Zhang, W., Cao, J., Cao, Y., Bi, X., Zhao, H., Zhang, Z., Liu, Z., Wan, T., Lang, R., et al. (2024) · BioScience Trends · doi:10.5582/bst.2024.01394 · Cited by 23
Self-citationImmunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy
Fasano, R., Shadbad, M. A., Brunetti, O., Argentiero, A., Calabrese, A., Nardulli, P., Calbi, R., Baradaran, B., & Silvestris, N. (2021) · Life · doi:10.3390/life11121355 · Cited by 24
Yau, T. C. C., Tai, D. W.-M., Chan, S. L., Huang, Y., Choo, S. P., Hsu, C., Cheung, T. T., Lin, S., Yong, W. P., Lee, J. J. X., et al. (2022) · Liver Cancer · doi:10.1159/000525582 · Cited by 23
Fong, K. Y., Zhao, J. J., Sultana, R., Lee, J. J. X., Lee, S. Y., Chan, S. L., Yau, T. C. C., Tai, D. W. M., Sundar, R., & Too, C. W. (2022) · Liver Cancer · doi:10.1159/000526639 · Cited by 23
Radiation therapy in the era of immune treatment for hepatocellular carcinoma
Chen, L., Zhang, R., Lin, Z., Tan, Q., Huang, Z., & Liang, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100079 · Cited by 22
Li, S., Wu, J., Wu, J., Fu, Y., Zeng, Z., Li, Y., Han, L., Liao, W., & Yan, M.-L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109771 · Cited by 23
Self-citationCao, Y., Tang, H., Hu, B., Zhang, W., Wan, T., Han, J., Jiao, T., Li, J., Li, X., Yang, Z., et al. (2023) · HPB · doi:10.1016/j.hpb.2023.03.004 · Cited by 23
Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review
Muscolino, P., Granata, B., Omero, F., Pasquale, C. D., Campana, S., Calabrò, A., D’Anna, F., Drommi, F., Pezzino, G., Cavaliere, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1247614 · Cited by 28
Chang, X., Wu, H., Ning, S., Li, X., Xie, Y., Shao, W., & Yu, J. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s418387 · Cited by 23
“In addition, sintilimab, camrelizumab and tislelizumab are three PD-1 inhibitors that have been approved by China Food and Drug Administration (CFDA) for HCC treatment.(14,40,41) In this study, patients received treatment regimens that included one of the three different PD-1 inhibitors.”
BackgroundLi, Z.-C., Wang, J., Liu, H.-B., Zheng, Y.-M., Huang, J.-H., Cai, J., Zhang, L., Liu, X., Du, L., Yang, X.-T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113877 · Cited by 24
Self-citationZhou, L., Yang, S., Li, Y., Xue, C., & Wan, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448728 · Cited by 23
Zhao, C., Zhang, Y., Wang, G., Zheng, J., Chen, W., Lu, Z., Li, Z., Gu, S., Han, L., Zheng, Z., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02333-5 · Cited by 25
“Currently, sintilimab (PD-1 inhibitor) and bevacizumab biosimilar (anti-VEGF) (ORIENT-32 study) 7 and camrelizumab (PD-1 inhibitor) and rivoceranib (TKI) (CARES-310 study).”
Self-citationWNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials
Lehrich, B. M., & Monga, S. P. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01127-y · Cited by 27
“Other phase III clinical trials with ICI combinations have resulted in similar efficacy and safety and tolerability, but have demonstrated worse clinical outcomes irrespective of patient subgroup analyses 38–41 .”
Liu, K., Wu, J., Xu, Y., Li, D., Huang, S., & Ye, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s383685 · Cited by 22
“Our study aimed to evaluate the efficacy of regorafenib with PD-1 inhibitors (RP) and regorafenib alone (R) as second-line treatment for advanced HCC. Methods: From October 2018 to January 2022, our retrospective study evaluated advanced HCC patients who received regorafenib with PD-1 inhibitors or regorafenib alone a…”
BackgroundInfluentialSelf-citationYang, T., Yu, Y.-F., Tsai, C., Li, H.-J., Yang, P., Huang, K., & Cheng, J. C. (2022) · BMC Cancer · doi:10.1186/s12885-022-10174-6 · Cited by 22
“However, there is growing evidence that the combination of targeted therapy and immunotherapy has the potential to provide synergistic and sustained effects for cancer management [12, 13] and for unresectable HCC [14, 15].”
BackgroundMethodHuang, D., Ke, L., Cui, H., & Su, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-10960-w · Cited by 24
“ORIENT-32 [23] study which was done for the Chinese population was only included in the Asian subgroup.”
BackgroundMethodResultInfluentialMeyers, B. M., Knox, J. J., Liu, D. M., McLeod, D., Ramjeesingh, R., Tam, V. C., & Lim, H. J. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102584 · Cited by 21
He, M., Huang, Y., Du, Z., Lai, Z., Ouyang, H., Shen, J., Wen, D., Li, Q., Zhang, Y., Wei, W., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0060 · Cited by 22
Self-citationXu, X., Wang, M.-D., Xu, J.-H., Fan, Z., Diao, Y., Chen, Z., Jia, H., Liu, F., Zeng, Y., Wang, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1322233 · Cited by 22
Self-citationDong, H., Zhang, Z., Ni, M., Xu, X., Luo, Y., Wang, Y., Zhang, H., & Chen, J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01246-9 · Cited by 24
“However, with the initiation of clinical trials such as IMbrave150, ORIENT32 and HIMALAYA since 2020, immunotherapy-based combination therapy has been gradually developed for advanced HCC [12–14].”
MethodSelf-citationXin, Y., Peng, G., Song, W., Zhou, X., Huang, X., & Cao, X. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1366131 · Cited by 25
Drug resistance in TKI therapy for hepatocellular carcinoma: Mechanisms and strategies
Jiang, X., Ge, X., Huang, Y., Xie, F., Chen, C., Wang, Z., Tao, W., Zeng, S., Lv, L., Zhan, Y., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217472 · Cited by 25
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
Yang, Z., Liu, Z., Liu, W., & Dong, X. C. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100218 · Cited by 29
Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction
Pathak, S., & Sonbol, M. B. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s268314 · Cited by 21
Zhang, Y., Wu, J., & Li, L. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100552 · Cited by 23
Self-citationLi, L., Yang, S., Chen, Y., Li, T., He, Y., Wu, B. Y., & Dong, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.891008 · Cited by 21
“Two phase III clinical trials [ORIENT-32 (Ren et al., 2021) and IMbrave150 (Finn et al.”
BackgroundMethodInfluentialSelf-citationCould We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
Lee, C., Chan, S., & Chon, H. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 19
“However, in a Chinese phase III trial conducted mostly for patients with B-viral HCC, those with BCLC-B or BCLC-C also benefitted from anti-PD-1 and anti-VEGF treatments relative to that from sorafenib treatment [37].”
BackgroundYang, X., Sun, Y.-Y., Li, D., Xu, G., & Huang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940009 · Cited by 21
“All the TRAEs were well-tolerated and consistent with previous reports (7, 15, 18, 19).”
BackgroundResultChinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Yang, Y. C., Sun, J., Wu, M., Lau, W. Y., Zheng, S., Wang, X., Chen, X., Fan, J., Dong, J., Cai, J., et al. (2022) · Liver Cancer · doi:10.1159/000526038 · Cited by 21
Self-citationInterventional radiology meets immuno-oncology for hepatocellular carcinoma
Salem, R., & Greten, T. F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.003 · Cited by 21
Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review
Damaskos, C., Garmpis, N., Dimitroulis, D., Garmpi, A., Psilopatis, I., Sarantis, P., Koustas, E., Kanavidis, P., Prevezanos, D., Kouraklis, G. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214117 · Cited by 22
Shao, T., Zhao, M., & Tang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.953671 · Cited by 21
Shen, J., Du, Y., Shao, R., & Jiang, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967182 · Cited by 21
“Sintilimab, a fully recombinant human IgG4 anti-PD1 monoclonal antibody, has been approved for the treatment of classical Hodgkin’s lymphoma, non-small cell lung cancer, and hepatocellular carcinoma by the National Medical Products Administration of China (Yang et al., 2020; Ren et al., 2021).”
BackgroundImmunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
Laface, C., Ranieri, G., Maselli, F. M., Ambrogio, F., Foti, C., Ammendola, M., Laterza, M., Cazzato, G., Memeo, R., Mastrandrea, G., et al. (2023) · Cancers · doi:10.3390/cancers15030654 · Cited by 21
“Numerous studies have evaluated some tumor characteristics, such as intact IFN-y signaling, high tumor mutation burden, presence of ICPs, and high levels of TILs, which have demonstrated a positive clinical response to immunotherapy [29,54,63,64,68].”
BackgroundLazzaro, A., & Hartshorn, K. L. (2023) · Cancers · doi:10.3390/cancers15092506 · Cited by 23
Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights
Yu, J. B., Park, R., & Kim, R. D. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s341195 · Cited by 23
“A biomarker study including RNA sequencing from the ORIENT-32 phase 2–3 RCT with a sintilimab (anti-PD-L1) and bevacizumab biosimilar combination is underway in China, but no interim data are available to date.(108)”
MethodVogel, A., Finn, R. S., Zumofen, M.-H. B., Heuser, C., Alvarez, J. S., Leibfried, M., Mitchell, C., Batson, S., Redhead, G., Gaillard, V. E., et al. (2023) · Liver Cancer · doi:10.1159/000533166 · Cited by 22
Zhang, J.-X., Hua, H.-J., Cheng, Y., Liu, S., Shi, H., & Zu, Q. (2023) · Academic Radiology · doi:10.1016/j.acra.2023.09.001 · Cited by 21
Zanuso, V., Pirozzi, A., Balsano, R., Pressiani, T., & Rimassa, L. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347932 · Cited by 21
Kudo, M. (2024) · Liver Cancer · doi:10.1159/000540801 · Cited by 24
“Sintilimab plus bevacizumab in ORIENT-32 trial [10] and camrelizumab plus rivoceranib from CARES-31 trial [11] are not FDA-approved agents.”
BackgroundDu, Q., Yuan, J., & Ren, Z. (2024) · Liver Cancer · doi:10.1159/000534446 · Cited by 20
“ICIs therapies showed signi fi cant improved survival versus TKIs in IMbrave 150 [6, 7] and ORIENT-32 [8] trials in the fi rst-line setting.”
BackgroundMethodSelf-citationZuo, M., Cao, Y., Yang, Y., Zheng, G., Li, D., Shao, H., Ma, Q., Song, P., An, C., & Li, W. (2024) · Hepatology International · doi:10.1007/s12072-024-10690-6 · Cited by 22
“%) of the above trials were lower than those of TRIPLET treatment [10, 12, 23].”
ResultSelf-citationWang, Y., Wu, Y., Zhang, H., Wang, J., Song, A., Qiu, H., Yuan, X., Xiong, H., & Zou, Y. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000064 · Cited by 21
Self-citationMei, J., Yang, K., Zhang, X., Luo, Z., Tian, M., Fan, H., Chu, J., Zhang, Y., Ding, J., Xu, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202409147 · Cited by 20
Self-citationMa, X., Zhuang, H., Wang, Q., Yang, L., Xie, Z., Zhang, Z., Tan, W., Tang, C., Chen, Y., & Shang, C. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s349966 · Cited by 20
“Another study showed that HCC patients receiving the combination therapy of sintilimab and a bevacizumab biosimilar (IBI305) had a longer median progressionfree survival than those receiving sorafenib.(4) However, approximately 75% of HCC patients show a weak response to”
ResultSelf-citationExpression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma
Fan, W., Ma, H., & Jin, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13266 · Cited by 21
Wang, J., Zheng, Z., Wu, T., Li, W., Wang, J., Pan, Y., Peng, W. J., Hu, D., Hou, J., Xu, L., et al. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s379326 · Cited by 20
Self-citationGong, H., Ong, S. C., Fan, L., Weng, Z., Zhao, K., & Jiang, Z. (2023) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-023-00435-x · Cited by 20
“More information on the inclusion and exclusion criteria is available elsewhere [9].”
BackgroundMethodZhang, C., Zeng, Z., Zhuo, M., Luo, J., Zhuang, X.-H., Xu, J.-N., Zeng, J., Ma, J., & Lin, H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad169 · Cited by 20
Self-citationLu, N., Jiang, Y.-F., Xia, W., Huang, Y., Xie, C., Xu, C., Ye, Y., Liu, G., Bei, W.-X., Ke, L., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102136 · Cited by 22
Self-citationKang, J., Jiang, J., Xiang, X., Zhang, Y., Tang, J., & Li, L. (2024) · Cancer Cell International · doi:10.1186/s12935-023-03189-x · Cited by 20
“Combining immune checkpoint inhibitors (ICIs) with vascular targeting therapy has demonstrated synergistic sensitization in the treatment of various tumors, including hepatocellular carcinoma [46, 47], Non-small cell lung cancer [48], gastric cancer [49].”
BackgroundWu, J., Wu, J., Li, S., Luo, M., Zeng, Z., Li, Y., Fu, Y., Li, H., Liu, D.-Y., Ou, X.-Y., et al. (2024) · BioScience Trends · doi:10.5582/bst.2023.01326 · Cited by 20
Self-citationLiu, X., Xia, F., Chen, Y., Sun, H., Yang, Z., Chen, B., Zhao, M. D., Bi, X., Peng, T., Ainiwaer, A., et al. (2024) · Liver Research · doi:10.1016/j.livres.2024.05.001 · Cited by 20
“15,117 Recommendation 17: Both liver cancer treatment and portal hypertension management should be established for patients with portal hypertension and liver cancer.”
Self-citationPang, B., Zuo, B., Huang, L., You, X., Liu, T., Hao, J., Yuan, C., Yang, C., Lau, W. Y., & Zhang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112492 · Cited by 20
Yang, Z., Fu, Y., Wang, Q., Pan, Y., Wang, J., Chen, J., Hu, D., Zhou, Z., Chen, M., & Zhang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001860 · Cited by 20
“…factor (anti-VEGF) agent bevacizumab and anti-programmed death 1 (anti-PD1) agent sintilimab plus bevacizumab both have shown signi fi cant enhancements in overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and quality of life when compared to sorafenib [6,7] .”
Self-citationNeoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
Akula, V., Chen, L., Açıkgöz, Y., Klein, K., Yavuz, B. G., Cevik, L., Demir, T., Manne, A., Şahin, İ., Kaseb, A. O., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00846-4 · Cited by 24
“Combination sintilimab (anti-PD-1) and bevacizumab (anti-VEGF) havealsoshownimprovedPFSandOScomparedtosorafenibwhenusedtotreatunresectableandadvancedHCCintheORIENT-32trial 36 .”
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 23
Argemí, J., Ponz‐Sarvisé, M., & Sangro, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.002 · Cited by 19
Ju, S., Zhou, C., Hu, J., Wang, Y., Wang, C., Liu, J., Yang, C., Huang, S., Li, T., Chen, Y., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09451-1 · Cited by 19
“Similarly, compared with sorafenib, the ORIENT-32 trial also demonstrated the advantages of combination therapy, possibly due to the synergy between anti-angiogenic drugs and anti-PD-1 antibodies [13].”
ResultSelf-citationLi, L., Wen, Q., & Ding, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905520 · Cited by 19
Wang, L., Ye, P., Qin, S., Wan, X., Zeng, X., Li, S., Liu, Q., & Tan, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279786 · Cited by 19
“Subsequently, many drugs have been approved for the first-line treatment of unresectable advanced HCC, including oral multikinase inhibitors sunitinib [9], brivanib [10], erlotinib [11], linifanib [12], lenvatinib [13] and donafenib [14], as well as immune checkpoint inhibitors (ICIs) atezolizumab [15] and sintilimab…”
BackgroundJiang, N., Zhong, B., Huang, J., Li, W.-C., Zhang, S., Zhu, X., Ni, C., & Shen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1205636 · Cited by 18
Chami, P., Diab, Y., Khalil, D. N., Azhari, H., Jarnagin, W. R., Abou‐Alfa, G. K., Harding, J. J., Hajj, J., Ma, J., Homsi, M. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316773 · Cited by 18
“…investigating the combination of sintilimab (anti-PD-1) plus IBI305 (a bevacizumab biosimilar) as first-line therapy revealed increased OS and PFS over sorafenib (median OS: NA vs. 10.4 months; median PFS: 4.6 months vs. 2.8 months; p < 0.0001) in patients with unresectable HBV-related HCC [26].”
BackgroundInfluentialTian, C., Yu, Y., Wang, Y., Yang, L., Tang, Y., Yu, C., Feng, G., Zheng, D., & Wang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352873 · Cited by 24
Self-citationLi, J.-X., Deng, W.-X., Huang, S., Lin, X., Long, M., Zhang, J., Su, T., Li, L., Pang, Y.-D., Liang, C., et al. (2022) · Radiation Oncology · doi:10.1186/s13014-022-02075-6 · Cited by 19
“4 months, 64%, and 4% in the ORIENT-32 study [29].”
Self-citationChen, Y., Du, C., Shen, S., Zhang, W., Shan, Y., Lyu, A., Wu, J., Shang, C., Luo, X., Wei, J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0006 · Cited by 19
Self-citationLi, J., Yang, B., Teng, Z., Liu, Y., Li, D., & Qu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430196 · Cited by 20
Jin, Z., Zhou, J., Chen, J., Ding, R., Scheiner, B., Wang, S., Li, H., Shen, Q., Lu, Q., Liu, Y., et al. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13615 · Cited by 21
Self-citationLi, X., Zhang, Q., Lu, Q., Cheng, Z., Liu, F., Han, Z., Yu, X., Yu, J., & Liang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023983 · Cited by 18
Tian, J.-C., Liu, H., Yan, L., Ding, Z., Han, C., Tian, B., Tan, S., Dong, Z., Wang, D., Xue, J.-S., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00938-6 · Cited by 19
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
Cammarota, A., Zanuso, V., Manfredi, G. F., Murphy, R., Pinato, D. J., & Rimassa, L. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148029 · Cited by 19
Zeng, H., Xu, Q., Wang, J., Xu, X., Luo, J. P., Zhang, L., Luo, C., Ying, J., & Li, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1073133 · Cited by 18
“Similarly, the anti-PD-1 antibody sintilimab plus bevacizumab versus sorafenib improved OS in Chinese patients (11).”
BackgroundResultSelf-citationZhu, H., Feng, J.-K., Xiang, Y., Wang, K., Zhou, L.-P., Liu, Z., Cheng, Y., Shi, J., Guo, W., & Cheng, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11003-0 · Cited by 19
“Eligibility criteria The inclusion criteria were [1] age ≥ 18 years; [2] unresectable HCC that was classified as Barcelona Clinic Liver Cancer (BCLC) stage B or C; [3] treatment-naive; [4] well-preserved liver function of Child-Pugh class A or B7; [5] had an Eastern Cooperative Oncology Group (ECOG) performance status…”
BackgroundMethodCelsa, C., Cabibbo, G., Pinato, D. J., Maria, G. D., Enea, M., Vaccaro, M., Battaglia, S. L., Rizzo, G. E. M., Giuffrida, P., Giacchetto, C. M., et al. (2023) · Liver Cancer · doi:10.1159/000531744 · Cited by 18
“…PFS, and quality of life [10, 11], establishing itself as the current standard of care for advanced HCC. Similar results were obtained with the combination of sintilimab, an anti-PD-1 agent, plus IBI305, a bevacizumab biosimilar, in a phase 3 RCT enrolling mostly patients with HBV infection [12].”
BackgroundResultInfluentialChen, X., Liu, X., & Du, S. (2023) · Cancers · doi:10.3390/cancers15205046 · Cited by 19
“In addition to the successful IMbravel150 trial, another study with a similar design, ORIENT-32 [36], was conducted as a randomized, open-label investigation.”
BackgroundMethodZang, M., Hu, X., Yuan, G., Li, R., Li, W., Pang, H., Li, Q., & Chen, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111019 · Cited by 18
Self-citationHepatocellular carcinoma: Advances in systemic therapies
Wu, T. K.-H., Hui, R. W., Mak, L., Fung, J., Seto, W., & Yuen, M. (2024) · F1000Research · doi:10.12688/f1000research.145493.1 · Cited by 21
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers
Cabibbo, G., Rimassa, L., Lamarca, Á., Masi, G., Daniele, B., Pinato, D. J., & Gardini, A. C. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102955 · Cited by 18
Zhang, X., Cai, H., Peng, W., Wang, H., Wu, J., Zhu, X., Weixin, G. U. O., Xie, F., Zhang, Y., Wang, M., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02498-z · Cited by 19
“Intravenous administration of sintilimab or camrelizumab (200 mg) 56,57 began two weeks post-TACE and was subsequently repeated on a three-week cycle.”
Self-citationLi, D., Xu, L., Ji, J., Bao, D., Hu, J., Qian, Y., Zhou, Y., Chen, Z., Li, D., Li, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944062 · Cited by 17
“A recent multi-center randomized controlled trial showed that sintilimab plus a bevacizumab biosimilar (IBI305) had significantly better efficacy than sorafenib in the treatment of unresectable HCC, with acceptable safety (16).”
BackgroundSelf-citationZhu, A. X., Lin, Y., Ferry, D. R., Widau, R. C., & Saha, A. (2022) · Immunotherapy · doi:10.2217/imt-2022-0089 · Cited by 17
Xu, B., Zhu, X., Shen, Y., Zhu, J., Liu, J., Li, M., Tang, P.-W., Zhou, J., Fan, J., Sun, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016736 · Cited by 17
Self-citationChen, Y., Hong, H., Fang, W., Zhang, X., Luo, H., Chen, Z., Yu, J., Fan, W., Chi, X., & Peng, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1113389 · Cited by 17
Self-citationImmune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
Carloni, R., Sabbioni, S., Rizzo, A., Ricci, A. D., Palloni, A., Petrarota, C., Cusmai, A., Tavolari, S., Gadaleta‐Caldarola, G., & Brandi, G. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s390963 · Cited by 18
“4 months).(23) By comparing ORIENT-32 study and the other two positive phase III trials, IMbrave-150 and SHR-1210-III-310, it emerged that mPFS and mOS of control arm (ie, sorafenib treated patients) in Chinese study were shorter.”
ResultA multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma
Lee, Y. R. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.09.04 · Cited by 17
Lang, W. J., Deng, L., Huang, B., Zhong, D., Zhang, G., Lu, M., & Ouyang, M. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01343-5 · Cited by 18
Zhang, J.-X., Cheng, Y., Wei, J., Fan, W.-L., Liu, J., Zhou, C., Liu, S., Shi, H., Chu, X., Zheng, W., et al. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03724-x · Cited by 17
Liu, Z., Yang, L., Liu, C., Wang, Z., Xu, W., Lu, J., Wang, C., & Xu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371829 · Cited by 17
“In this context, two extensive clinical trials have demonstrated that combining ICIs and VEGFR-targeted drugs is superior to sorafenib in treating patients with advanced HCC (4, 5).”
Self-citationZarlashat, Y., Mushtaq, H., Pham, L., Abbas, W., & Sato, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136830 · Cited by 19
“The authors found a higher median PFS of 4.6 months for the combination therapy in comparison to 2.8 months for sorafenib monotherapy [87].”
BackgroundResultInfluentialWang, Y., Sandrine, I. K., Ma, L., Chen, K., Chen, X., Yu, Y., Wang, S., Xiao, L., Li, C., Liu, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06897-y · Cited by 17
Self-citationGuo, G., Zhang, Z., Zhang, J., Wang, D., Xu, S., Liu, G., Gao, Y., Mei, J., Yan, Z., Ruijiao, Z., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03774-7 · Cited by 18
Lu, Y.-C., Yang, Y.-C., Ma, D., Wang, J., Hao, F., Chen, X., & Chen, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471017 · Cited by 19
Self-citationXu, J., Li, J., Wang, T., Luo, X., Zhu, Z., Wang, Y., Wang, Y., Zhang, Z., Song, R., Yang, L., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13978-4 · Cited by 18
Self-citationAdvances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review
Reiter, F. P., Khaled, N. B., Ye, L., Zhang, C., Seidensticker, M., den Winkel, M. O., Denk, G., Geier, A., & Toni, E. N. D. (2021) · Digestive Diseases · doi:10.1159/000520095 · Cited by 17
Ding, X., Li, G., Sun, W., Shen, Y., Teng, Y., Xu, Y., Li, W., Liu, M., & Chen, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.907055 · Cited by 16
“In addition, the success of the combination of immune checkpoint inhibitors, such as sintilimab with a bevacizumab biosimilar (IBI 305) (8) or pembrolizumab plus lenvatinib (9, 10), have been reported in unresectable hepatocellular carcinoma.”
BackgroundLei, Q., Yan, X. C., Zou, H., Jiang, Y., Lai, Y., Ung, C. O. L., & Hu, H. (2022) · Discover Oncology · doi:10.1007/s12672-022-00559-1 · Cited by 16
“4, six cohorts from five studies compared ICIs-based immunotherapy with TKIs, and all of them chose sorafenib as the control group [13, 33, 36, 50, 54].”
BackgroundAdvanced development of biomarkers for immunotherapy in hepatocellular carcinoma
Peng, X., Gong, C., Zhang, W., & Zhou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1091088 · Cited by 16
Metadata
- Authors
- Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., Chen, Z., Liu, B., Jia, W., Wu, J., Wang, J., Shao, G., Zhang, B., Shan, Y., Meng, Z., Wu, J., Gu, S., Yang, W., Liu, C., Shi, X., Gao, Z., Yin, T., Cui, J., Huang, M., Xing, B., Mao, Y., Teng, G., Qin, Y., Wang, J., Xia, F., Yin, G., Yang, Y., Chen, M., Wang, Y., Zhou, H., & Fan, J.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Chinese PLA General Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Nantong University (CN)
- Henan Provincial People's Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Sichuan University (CN)
- Sun Yat-sen University (CN)
- Nanfang Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Nanjing Drum Tower Hospital (CN)
- Anhui Provincial Hospital (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Zhejiang Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Fudan University (CN)
- Hunan Cancer Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Shandong Tumor Hospital (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Hubei Cancer Hospital (CN)
- First Hospital of Jilin University (CN)
- Peking Union Medical College Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Southwest Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Innovent Biologics (China) (CN)
- Corresponding author
- Fan, Jia
- ORCID
- Ren, Zhenggang
- Xu, Jianming
- Bai, Yuxian
- Xu, Aibing
- Cang, Shundong
- Du, Chengyou
- Li, Qiu
- Lu, Yinying
- Chen, Yajin
- Guo, Yabing
- Chen, Zhendong
- Liu, Baorui
- Jia, Weidong
- Wu, Jian
- Wang, Junye
- Shao, Guoliang
- Zhang, Bixiang
- Shan, Yunfeng
- Meng, Zhiqiang
- Wu, Jianbing
- Gu, Shanzhi
- Yang, Wei
- Liu, Chao
- Gao, Zhenyuan
- Yin, Tao
- Cui, Jiuwei
- Huang, Ming
- Mao, Yilei
- Qin, Yanru
- Wang, Jinhai
- Yin, Guowen
- Yang, Yong
- Chen, Mingxia
- Zhou, Hui
- Fan, Jia
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 22
- Issue
- 7
- Pages
- 977-990
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3166753505
- Cited by
- 1,124
- References
- 30
- Citations by year
- 2026: 162 · 2025: 241 · 2024: 273 · 2023: 247 · 2022: 178 · 2021: 21
- FWCI
- 100.04
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-08-01)
- Open access
- closed
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- sintilimab, bevacizumab biosimilar, sorafenib, hepatocellular carcinoma, PD-1 inhibitors, first-line therapy, unresectable liver cancer, hepatitis B virus, overall survival, progression-free survival, combination immunotherapy, anti-angiogenic therapy, China, safety and tolerability, macrovascular invasion
- MeSH terms
- Bevacizumab, Sorafenib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, China, Female, Hepatitis B, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Time Factors, Disease Progression, Young Adult, Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
